Friday Hope: Eriodictyol: Found in Citrus Fruits, This Flavonoid Downregulates ACE2, TMPRSS2 and TGF-Β

Key Takeaways

• Eriodictyol lowers ACE2 and TMPRSS2 expression in cell assays
• Reduces TGF‑β and collagen deposition in rat kidney fibrosis model
• Inhibits amyloid‑β aggregation and tau phosphorylation in mouse brain
• Acts as antioxidant, anti‑inflammatory, and cardioprotective flavonoid
• Potential low‑cost nutraceutical for acute and long‑COVID management

Pulse Analysis

Eriodictyol, a flavanone abundant in lemons, oranges, and several medicinal plants, is gaining attention for its ability to interfere with SARS‑CoV‑2 entry mechanisms. Laboratory data demonstrate that the compound suppresses the expression of ACE2 and TMPRSS2, the two surface proteins the virus exploits to infect cells. By blocking this interaction, eriodictyol could reduce viral load in early infection stages, offering a complementary approach to vaccines and antivirals, especially for populations seeking natural adjuncts.

Beyond antiviral activity, eriodictyol shows promise in addressing the fibrotic sequelae linked to spike‑protein toxicity. Pre‑clinical studies in doxorubicin‑treated rats reported lowered TGF‑β1 mRNA, diminished collagen deposition, and improved kidney function after eriodictyol administration. These findings suggest the flavonoid may curb organ scarring that underlies many long‑COVID complications, positioning it as a candidate for anti‑fibrotic drug development or functional‑food formulations aimed at post‑viral recovery.

Neuroprotective properties further broaden eriodictyol’s therapeutic appeal. In APP/PS1 mouse models of Alzheimer’s disease, the compound reduced amyloid‑β aggregation, tau hyperphosphorylation, and oxidative stress via activation of the Nrf2/HO‑1 pathway. Given emerging evidence that spike proteins can trigger neuroinflammation and protein misfolding, eriodictyol’s dual antiviral and neuroprotective actions could fill a critical gap in managing the cognitive deficits reported by long‑COVID sufferers. Investors and biotech firms may therefore view eriodictyol as a versatile scaffold for next‑generation nutraceuticals or prescription agents targeting viral entry, fibrosis, and neurodegeneration.